{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:58:39Z","timestamp":1781643519083,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mongolia has a high prevalence of liver disease from chronic viral hepatitis infections, which can compromise the immune response. It is unclear whether people with chronic liver disease produce a robust antibody response to the COVID-19 vaccines. We investigated whether the antibody response to the COVID-19 booster vaccination differed between those with and without chronic viral hepatitis from multiple viral types.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants from Mongolia were recruited to the International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE). Demographic information was recorded and participants\u2019 SARS-CoV2 anti-Spike antibody levels were measured at visit 1 (prior to administration of booster vaccine at baseline) and visit 2 (approximately 2 +\/-1 months after booster vaccination). We used linear regression to determine if the anti-Spike antibody responses differed between participants with and without different types of chronic viral hepatitis infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, there was no significant difference in the anti-Spike antibody response between participants with and without chronic viral hepatitis, a result suggesting that COVID-19 vaccine booster immunogenicity is not affected by chronic hepatitis. Participants with chronic HCV infection produced a robust antibody response, but based on our linear regression analysis, this response seemed to wane faster than in participants without chronic viral hepatitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our finding that there was no significant difference in the anti-Spike antibody response between participants with and without chronic viral hepatitis adds to the evidence that the COVID-19 vaccines are immunogenic in people with chronic viral hepatitis, including in those with HBV\/HDV coinfection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-13095-y","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T04:07:43Z","timestamp":1774325263000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 vaccine immunogenicity in Mongolian adults with and without chronic hepatitis"],"prefix":"10.1186","volume":"26","author":[{"given":"Viviane","family":"Callier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganbolor","family":"Jargalsaikhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munguntsetseg","family":"Batkhuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Ridzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Hunsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irini","family":"Sereti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Shaw-Saliba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shera","family":"Weyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naranjaral","family":"Dashdorj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"7","key":"13095_CR1","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.cgh.2021.12.022","volume":"20","author":"J Ai","year":"2022","unstructured":"Ai J, Wang J, Liu D, Xiang H, Guo Y, Lv J, Zhang Q, Li J, Zhang X, Li Q, Liang J, Guo X, Feng Y, Liu L, Zhang X, Qin W, Wang X, Rao W, Zhang Q, Qi X. Safety and immunogenicity of SARS-CoV-2 vaccines in patients with chronic liver diseases (CHESS-NMCID 2101): a multicenter study. Clin Gastroenterol Hepatol. 2022;20(7):1516\u2013e15241512. https:\/\/doi.org\/10.1016\/j.cgh.2021.12.022.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"13095_CR2","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.jhep.2014.08.010","volume":"61","author":"A Albillos","year":"2014","unstructured":"Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61(6):1385\u201396. https:\/\/doi.org\/10.1016\/j.jhep.2014.08.010.","journal-title":"J Hepatol"},{"key":"13095_CR3","doi-asserted-by":"publisher","unstructured":"Bakasis AD, Bitzogli K, Mouziouras D, Pouliakis A, Roumpoutsou M, Goules AV, Androutsakos T. Antibody responses after SARS-CoV-2 vaccination in patients with liver diseases. Viruses. 2022;14(2). https:\/\/doi.org\/10.3390\/v14020207.","DOI":"10.3390\/v14020207"},{"key":"13095_CR4","doi-asserted-by":"publisher","unstructured":"Cao H, Huang Y, Zhong C, Liao X, Tan W, Zhao S, Guo L, Fan R. Antibody response and safety of inactivated SARS-CoV-2 vaccines in chronic hepatitis B patients with and without cirrhosis. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1167533.","DOI":"10.3389\/fimmu.2023.1167533"},{"key":"13095_CR5","unstructured":"CDC. (2021). Hepatitis C, Chronic 2020 Case Definition. https:\/\/ndc.services.cdc.gov\/case-definitions\/hepatitis-c-chronic-2020\/."},{"issue":"6","key":"13095_CR6","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/hep.28957","volume":"66","author":"X Chen","year":"2017","unstructured":"Chen X, Oidovsambuu O, Liu P, Grosely R, Elazar M, Winn VD, Fram B, Boa Z, Dai H, Dashtseren B, Yagaanbuyant D, Genden Z, Dashdorj N, Bungert A, Dashdorj N, Glenn JS. A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus\u2013infected mongolians. Hepatology. 2017;66(6):1739\u201349. https:\/\/doi.org\/10.1002\/hep.28957.","journal-title":"Hepatology"},{"issue":"4","key":"13095_CR7","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3350\/cmh.2022.0087","volume":"28","author":"KS Cheung","year":"2022","unstructured":"Cheung KS, Mok CH, Mao X, Zhang R, Hung IFN, Seto WK, Yuen MF. COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis. Clin Mol Hepatol. 2022;28(4):890\u2013911. https:\/\/doi.org\/10.3350\/cmh.2022.0087.","journal-title":"Clin Mol Hepatol"},{"issue":"5","key":"13095_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/14787210.2019.1604221","volume":"17","author":"S Chevallez","year":"2019","unstructured":"Chevallez S. Strategies for the improvement of HCV testing and diagnosis. Expert Rev Anti-infective Therapy. 2019;17(5):341\u20137.","journal-title":"Expert Rev Anti-infective Therapy"},{"issue":"9","key":"13095_CR9","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","volume":"7","author":"GBDHB Collaborators","year":"2022","unstructured":"Collaborators GBDHB. Global, regional, and national burden of hepatitis B, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796\u2013829. https:\/\/doi.org\/10.1016\/S2468-1253(22)00124-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"13095_CR10","doi-asserted-by":"publisher","first-page":"113488","DOI":"10.1016\/j.jim.2023.113488","volume":"517","author":"D Dabitao","year":"2023","unstructured":"Dabitao D, Shaw-Saliba K, Konate DS, Highbarger HC, Lallemand P, Sanogo I, Rehman T, Wague M, Coulibaly N, Kone B, Baya B, Diakite SAS, Samake S, Akpa E, Tounkara M, Laverdure S, Doumbia S, Lane HC, Diakite M, Dewar RL. Clinical evaluation of commercial SARS-CoV-2 serological assays in a malaria endemic setting. J Immunol Methods. 2023;517:113488. https:\/\/doi.org\/10.1016\/j.jim.2023.113488.","journal-title":"J Immunol Methods"},{"issue":"9","key":"13095_CR11","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/jvh.12697","volume":"24","author":"B Dashtseren","year":"2017","unstructured":"Dashtseren B, Bungert A, Bat-Ulzii P, Enkhbat M, Lkhagva-Ochir O, Jargalsaikhan G, Enkhbat A, Oidovsambuu O, Klemen J, Dashdorj N, Dashdorj N, Genden Z, Yagaanbuyant D. Endemic prevalence of hepatitis B and C in Mongolia: a nationwide survey amongst mongolian adults. J Viral Hepat. 2017;24(9):759\u201367. https:\/\/doi.org\/10.1111\/jvh.12697.","journal-title":"J Viral Hepat"},{"issue":"8","key":"13095_CR12","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1007\/s10620-020-06499-6","volume":"66","author":"T Fong","year":"2021","unstructured":"Fong T, Lee BT, Chang M, Nasanbayar K, Tsogtoo E, Boldbaatar D, Dashdorj ED, Clifford NE, Dashdorj AN, Bang BR, Chida T, Lim C, Sugiyama M, Mizokami M, Dashdorj N, Liu P, Glenn JS, Dashdorj N, Saito T. High Prevalence of chronic viral hepatitis and liver fibrosis among mongols in Southern California. Dig Dis Sci. 2021;66(8):2833\u2013939. https:\/\/doi.org\/10.1007\/s10620-020-06499-6.","journal-title":"Dig Dis Sci"},{"key":"13095_CR13","doi-asserted-by":"publisher","unstructured":"Giambra V, Piazzolla AV, Cocomazzi G, Squillante MM, De Santis E, Totti B, Cavorsi C, Giuliani F, Serra N, Mangia A. Effectiveness of booster dose of anti SARS-CoV-2 BNT162b2 in cirrhosis: longitudinal evaluation of humoral and cellular response. Vaccines (Basel). 2022;10(8). https:\/\/doi.org\/10.3390\/vaccines10081281.","DOI":"10.3390\/vaccines10081281"},{"issue":"1","key":"13095_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.13091","volume":"310","author":"D Goldblatt","year":"2022","unstructured":"Goldblatt D, Alter G, Crotty S, Plotkin SA. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol Rev. 2022;310(1):6\u201326. https:\/\/doi.org\/10.1111\/imr.13091.","journal-title":"Immunol Rev"},{"issue":"10","key":"13095_CR15","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.7326\/M22-0924","volume":"175","author":"A-TS Group","year":"2022","unstructured":"Group A-TS, Rogers AJ, Wentworth D, Phillips A, Shaw-Saliba K, Dewar RL, Aggarwal NR, Babiker AG, Chang W, Dharan NJ, Davey VJ, Higgs ES, Gerry N, Ginde AA, Hayanga JWA, Highbarger H, Highbarger JL, Jain MK, Kan V, Lundgren JD. The association of baseline plasma SARS-CoV-2 nucleocapsid antigen level and outcomes in patients hospitalized with COVID-19. Ann Intern Med. 2022;175(10):1401\u201310. https:\/\/doi.org\/10.7326\/M22-0924.","journal-title":"Ann Intern Med"},{"issue":"6","key":"13095_CR16","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/liv.15173","volume":"42","author":"T He","year":"2022","unstructured":"He T, Zhou Y, Xu P, Ling N, Chen M, Huang T, Zhang B, Yang Z, Ao L, Li H, Chen Z, Zhang D, Shi X, Lei Y, Wang Z, Zeng W, Hu P, Lan Y, Zhou Z, Ren H. Safety and antibody response to inactivated COVID-19 vaccine in patients with chronic hepatitis B virus infection. Liver Int. 2022;42(6):1287\u201396. https:\/\/doi.org\/10.1111\/liv.15173.","journal-title":"Liver Int"},{"key":"13095_CR17","doi-asserted-by":"publisher","first-page":"106985","DOI":"10.1016\/j.ijid.2024.106985","volume":"142","author":"S Laverdure","year":"2024","unstructured":"Laverdure S, Kazadi D, Kone K, Callier V, Dabitao D, Dennis D, Haidara MC, Hunsberger S, Mbaya OT, Ridzon R, Sereti I, Shaw-Saliba K, In VS T. SARS-CoV-2 seroprevalence in vaccine-naive participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali. Int J Infect Dis. 2024;142:106985. https:\/\/doi.org\/10.1016\/j.ijid.2024.106985.","journal-title":"Int J Infect Dis"},{"issue":"27","key":"13095_CR18","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.3748\/wjg.v25.i27.3527","volume":"25","author":"TY Li","year":"2019","unstructured":"Li TY, Yang Y, Zhou G, Tu ZK. Immune suppression in chronic hepatitis B infection associated liver disease: a review. World J Gastroenterol. 2019;25(27):3527\u201337. https:\/\/doi.org\/10.3748\/wjg.v25.i27.3527.","journal-title":"World J Gastroenterol"},{"key":"13095_CR19","doi-asserted-by":"publisher","unstructured":"Link-Gelles R, Weber ZA, Reese SE, Payne AB, Gaglani M, Adams K, Kharbanda AB, Natarajan K, DeSilva MB, Dascomb K et al. Estimates of bivalent mRNA vaccine durability in preventing COVID-19\u2013associated hospitalization and critical illness among adults with and without immunocompromising conditions \u2014 VISION Network, September 2022\u2013April 2023. MMWR Morb Mortal Wkly Rep, 2023;72(21):579\u2013588. https:\/\/doi.org\/10.15585\/mmwr.mm7221a3","DOI":"10.15585\/mmwr.mm7221a3"},{"key":"13095_CR20","doi-asserted-by":"publisher","unstructured":"Liu Q, Liu M, Liu J. Burden and trends of acute viral hepatitis in Asia from 1990 to 2019. Viruses. 2022;14(6). https:\/\/doi.org\/10.3390\/v14061180.","DOI":"10.3390\/v14061180"},{"issue":"3","key":"13095_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jhep.2020.09.024","volume":"74","author":"T Marjot","year":"2021","unstructured":"Marjot T, Moon AM, Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ, Pose E, Brenner EJ, Cargill T, Catana MA, Dhanasekaran R, Eshraghian A, Garcia-Juarez I, Gill US, Jones PD, Kennedy J, Marshall A, Matthews C, Mells G, Webb GJ. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol. 2021;74(3):567\u201377. https:\/\/doi.org\/10.1016\/j.jhep.2020.09.024.","journal-title":"J Hepatol"},{"issue":"1","key":"13095_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40001-022-00648-5","volume":"27","author":"MM Mehrabi Nejad","year":"2022","unstructured":"Mehrabi Nejad MM, Moosaie F, Dehghanbanadaki H, Haji Ghadery A, Shabani M, Tabary M, Aryannejad A, SeyedAlinaghi S, Rezaei N. Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis. Eur J Med Res. 2022;27(1):23. https:\/\/doi.org\/10.1186\/s40001-022-00648-5.","journal-title":"Eur J Med Res"},{"key":"13095_CR23","doi-asserted-by":"crossref","unstructured":"Mukesh RK, Yinda CK, Musnter VJ, van Doremalen N. Beyond COVID-19: the promise of next-generation coronavirus vaccines. npj Viruses, 2024;2.","DOI":"10.1038\/s44298-024-00043-3"},{"issue":"8","key":"13095_CR24","doi-asserted-by":"publisher","first-page":"e461","DOI":"10.1016\/S2665-9913(23)00160-1","volume":"5","author":"FA Pearce","year":"2023","unstructured":"Pearce FA, Lim SH, Bythell M, Lanyon P, Hogg R, Taylor A, Powter G, Cooke GS, Ward H, Chilcot J, Thomas H, Mumford L, McAdoo SP, Pettigrew GJ, Lightstone L, Willicombe M. Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY. Lancet Rheumatol. 2023;5(8):e461\u201373. https:\/\/doi.org\/10.1016\/S2665-9913(23)00160-1.","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"13095_CR25","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.jhep.2021.01.014","volume":"74","author":"M Rizzetto","year":"2021","unstructured":"Rizzetto M, Hamid S, Negro F. The changing context of hepatitis D. J Hepatol. 2021;74(5):1200\u201311. https:\/\/doi.org\/10.1016\/j.jhep.2021.01.014.","journal-title":"J Hepatol"},{"issue":"1","key":"13095_CR26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.cgh.2021.09.003","volume":"20","author":"DF Ruether","year":"2022","unstructured":"Ruether DF, Schaub GM, Duengelhoef PM, Haag F, Brehm TT, Fathi A, Wehmeyer M, Jahnke-Triankowski J, Mayer L, Hoffmann A, Fischer L, Addo MM, Lutgehetmann M, Lohse AW, Zur Wiesch S, J., Sterneck M. SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients. Clin Gastroenterol Hepatol. 2022;20(1):162\u2013e172169. https:\/\/doi.org\/10.1016\/j.cgh.2021.09.003.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"13095_CR27","doi-asserted-by":"publisher","first-page":"e0273914","DOI":"10.1371\/journal.pone.0273914","volume":"17","author":"I Sereti","year":"2022","unstructured":"Sereti I, Shaw-Saliba K, Dodd LE, Dewar RL, Laverdure S, Brown S, Mbaya OT, Tamfum M, Mblala-Kingebeni JJ, Sow P, Akpa Y, Haidara E, Tchos MCF, Beavogui K, Neal AH, Arlinda A, Lokida D, Grue D, Smolskis L, Hunsberger M, S. Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE). PLoS ONE. 2022;17(9):e0273914. https:\/\/doi.org\/10.1371\/journal.pone.0273914.","journal-title":"PLoS ONE"},{"issue":"8","key":"13095_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nri.2016.69","volume":"16","author":"EC Shin","year":"2016","unstructured":"Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016;16(8):509\u201323. \thttps:\/\/doi.org\/10.1038\/nri.2016.69.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"13095_CR29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.bpg.2017.04.009","volume":"31","author":"CH Siederdissen","year":"2017","unstructured":"Siederdissen CH, Maasoumy B, Cornberg M. What is new on HBsAg and other diagnostic markers in HBV infection? Best Pract Res Clin Gastroenterol. 2017;31(3):281\u20139.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"6","key":"13095_CR30","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.jhep.2021.08.008","volume":"75","author":"PJ Thuluvath","year":"2021","unstructured":"Thuluvath PJ, Robarts P, Chauhan M. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. J Hepatol. 2021;75(6):1434\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2021.08.008.","journal-title":"J Hepatol"},{"key":"13095_CR31","unstructured":"WHO. (2024). Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. https:\/\/iris.who.int\/bitstream\/handle\/10665\/376353\/9789240090903-eng.pdf?sequence=1."},{"key":"13095_CR32","unstructured":"WHO. (2022). Global Health Observatory: Hepatitis https:\/\/www.who.int\/data\/gho\/data\/themes\/chronic-viral-hepatitis."},{"key":"13095_CR33","doi-asserted-by":"publisher","first-page":"1078666","DOI":"10.3389\/fmed.2023.1078666","volume":"10","author":"S Wu","year":"2023","unstructured":"Wu S, Wang X, Feng M, Liu X, Fan X, Ran X, Wang B, Wang H. Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimer-based COVID-19 vaccine ZF2001 in chronic hepatitis B patients. Front Med (Lausanne). 2023;10:1078666. https:\/\/doi.org\/10.3389\/fmed.2023.1078666.","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"13095_CR34","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1038\/s41423-021-00795-5","volume":"18","author":"T Xiang","year":"2021","unstructured":"Xiang T, Liang B, Wang H, Quan X, He S, Zhou H, He Y, Yang D, Wang B, Zheng X. Safety and immunogenicity of a SARS-CoV-2 inactivated vaccine in patients with chronic hepatitis B virus infection. Cell Mol Immunol. 2021;18(12):2679\u201381. https:\/\/doi.org\/10.1038\/s41423-021-00795-5.","journal-title":"Cell Mol Immunol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13095-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13095-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13095-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:44:25Z","timestamp":1781642665000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13095-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13095"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13095-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was conducted in accordance with the Declaration of Helsinki. The main InVITE study protocol and each of the site-specific appendices received approval from the Independent Ethics Committee, Ministry of Health, Ulaanbaatar, Mongolia. The approval decree from the IEC for this study is 265. All study participants signed an informed consent in a language they understand prior to initiation of any study procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"866"}}